A coalition of community groups push to end AIDS at the epicenter of the U.S. epidemic Beginning in January 2013, a coalition of New York HIV/AIDS leaders came together to begin a series of discussions to reenvision the state’s HIV/AIDS…
Getting more HIV-positive people linked to and retained in care requires innovation and research By Tim Horn Viral-load suppression remains the holy grail of HIV care. Its associations with AIDS-free survival and a profound reduction in transmission risk are well…
President Obama orders multiagency cooperation to achieve National HIV/AIDS Strategy goals, but without required funding commitment By Scott Morgan If the United States is to effectively move toward the 2015 goals outlined in the National HIV/AIDS Strategy (NHAS) through the…
Bold strategies are required to remedy frequent stock-outs and supply interruptions By Lindsay McKenna Drug shortages, especially of tuberculosis (TB) drugs, have become increasingly common in the United States. Over the past year alone, the U.S. Centers for Disease Control…
Funding cuts and shifting budgetary priorities threaten tuberculosis gains By Coco Jervis The United States is losing ground in its fight against the tuberculosis (TB) epidemic within its own borders. Sequestration and shifting priorities of Congress and the Obama administration…
By Mark Harrington In death one can’t be vocal or witness time and motion and physical events with breath, one can’t make change. Abstract ideas of energy dispersing, some ethical ocean crawls through a funnel of stars, outlines of the…
The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.
Health insurance co-payment (co-pay) programs and patient drug assistance programs (PAPs) are critical services for thousands of U.S. residents with HIV and/or viral hepatitis who face out-of-pocket expenses associated with their treatment. The Fair Pricing Coalition (FPC) has negotiated co-pay…
Simultaneous, not sequential, evaluations of novel drug regimens needed to speed TB treatment research By Lindsay McKenna An example of a multi-arm multi-stage (MAMS) phase II trial design. At the first interim analysis, novel regimen 2 is considered to lack…
Rifapentine’s manufacturer helps to advance TB research while stalling access By Erica Lessem Sanofi-Aventis, manufacturer of the tuberculosis (TB) drug rifapentine (Priftin), can be credited for aiding research efforts to shorten and simplify treatment dosing for TB. However, the company’s…